TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02381262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
Study: NCT02233894

Intervention type: DRUG
Intervention: Atrovent® - inhalets
Study: NCT02010567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if \<T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
Study: NCT05008367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24 mg intravenous Dexamethasone (6 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24 mg intravenous Dexamethasone (6 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: 6 ml of isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: 6 ml of isotonic saline
Study: NCT04043416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivating reminiscence technology
Description: The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivating reminiscence technology
Description: The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
Study: NCT01359527

Intervention type: DEVICE
Intervention: Hip Resurfacing

Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Study: NCT04093193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement
Description: Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
Study: NCT01555073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin/celecoxib
Description: pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
Study: NCT03951402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching moxifloxacin capsule
Description: Matching placebo capsule to moxifloxacin capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching moxifloxacin capsule
Description: Matching placebo capsule to moxifloxacin capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Moxifloxacin tablet (overencapsulated)
Description: Overencapsulated 400 mg Moxifloxacin tablet.
Study: NCT01530568

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xpert
Description: This arm receives the GeneXpert test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smear
Description: This arm receives smear microscopy
Study: NCT02863029

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flexible Sigmoidoscopy
Description: A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
Study: NCT04633694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: insect, pea or whey protein
Description: The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: insect, pea or whey protein
Description: The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: insect, pea or whey protein
Description: The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
Study: NCT01550302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Single dose of 37.5 mg of bupivacaine subcutaneously
Study: NCT02343627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVXT Solution
Description: NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study: NCT01541540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Counseling plus Usual Care
Description: 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
Study: NCT00621244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT04644679

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7-day electrocardiographic monitoring
Description: 7-day external electrocardiographic monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 48-hr electrocardiographic monitoring
Description: 48-hr external electrocardiographic monitoring
Study: NCT03202992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
Study: NCT03394534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA group
Description: CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
Study: NCT00621244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03245840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension
Description: BOS 10 mL twice daily.
Study: NCT02111954

Intervention type: DIAGNOSTIC_TEST
Intervention: 1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
Description: Each patient will have two PET/CT
Study: NCT04913792

Intervention type: DEVICE
Intervention: ZXR00
Description: This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
Study: NCT01555073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin/placebo
Description: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib/placebo
Description: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Study: NCT04379687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Use of virtual reality glasses for balance work
Study: NCT04387695

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+TACE+Sorafenib
Description: SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 800 mg/day orally
Study: NCT04379687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Balance treatment with according to Bayouk physiotherapy
Study: NCT02340858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife LEDC System
Description: Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
Study: NCT04475523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-8993
Description: CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
Study: NCT03287882

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (UNIMMAP composition)
Description: The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills based education
Description: The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
Study: NCT01437579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intratrigonal injection of botulinum toxin
Description: Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cystoscopy
Description: cystoscopy under general anesthesia
Study: NCT02600416

Intervention type: OTHER
Group type: OTHER
Intervention: AV port reversal
Description: Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
Study: NCT02705846

Intervention type: OTHER
Intervention: Observation of treatment outcomes via Questionnaire
Description: Collection of treatment data from participants

Intervention type: OTHER
Intervention: Observation of treatment outcomes via Questionnaire
Description: Collection of treatment data from participants
Study: NCT01978054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissemination of public health knowledge
Description: State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
Study: NCT02302248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourcing reappraisal intervention
Description: 3 week access to a web-based crowdsourcing reappraisal platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing intervention
Description: 3 week access to a web-based expressive writing platform.
Study: NCT03049358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic Testing
Description: Undergo UPSIT smell test

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiologic Testing
Description: Undergo UPSIT smell test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Procedure
Description: Undergo olfactory training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rose essential oil
Description: patient smells rose oil in vial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lemon essential oil
Description: patient smells lemon oil in vial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove essential oil
Description: patient smells clove oil in vial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eucalyptus essential oil
Description: patient smells eucalyptus oil in vial

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: canola oil placebo
Description: patient smells canola oil in vial
Study: NCT04966312

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative educational videos plus routine education
Description: Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative routine education
Description: Mothers receiving routine education before their children receiving congenital heart disease surgery
Study: NCT02027311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
Study: NCT01114087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Description: Imatinib is a tyrosin-kinase inhibitor
Study: NCT00887367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: Two 175 mg doses of GSK598809 will be given.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
Study: NCT01679600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise
Description: Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotics-assisted treadmill exercise
Description: Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
Study: NCT01496326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10% ibuprofen cream formulation at a dose of 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 grams of placebo cream for 14 days
Study: NCT04334135

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Four to eight 20mg capsules (depending on body mass)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Four to eight 20mg capsules (depending on body mass)